Another damning report by an Indian parliamentary panel on clinical trials, this time with scathing comments against the US-based non-profit organization PATH over the conduct of studies concerning human papillomavirus (HPV) vaccines, could potentially have serious implications for Merck & Co's Gardasil and GlaxoSmithKline's Cervarix vaccines in the country1.
The parliamentary panel report also has some strong words against the Indian Council of Medical Research and the Drugs Controller...




